Literature DB >> 2454472

Three-dimensional model of the capsid proteins of two biologically different Theiler virus strains: clustering of amino acid difference identifies possible locations of immunogenic sites on the virion.

D C Pevear1, M Luo, H L Lipton.   

Abstract

To explore structural features of the Theiler murine encephalomyelitis virion, we have constructed a three-dimensional model of the capsid proteins (VP1, VP2, and VP3) of the BeAn strain based on the atomic coordinates of the closely related Mengo virus. By superimposition of amino acid differences between BeAn virus and another Theiler virus strain, GDVII, on the three-dimensional model, clusters of differences were found in four distinct sites; the VP1 third corner, the VP2 "puff," and the VP3 first corner and "knob." These clusters, which are found on the surface of the virion, may represent neutralizing immunogenic sites that have come under selective pressure from neutralizing antibodies. Furthermore, the putative viral receptor binding site ("pit") of the two Theiler virus strains was found to be markedly conserved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454472      PMCID: PMC280457          DOI: 10.1073/pnas.85.12.4496

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Identification of a new neutralization antigenic site on poliovirus coat protein VP2.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

3.  Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.

Authors:  M Ferguson; P D Minor; D I Magrath; Y H Qui; M Spitz; G C Schild
Journal:  J Gen Virol       Date:  1984-01       Impact factor: 3.891

4.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

5.  Characterization of Theiler's murine encephalomyelitis virus RNA.

Authors:  E J Rozhon; H L Lipton; F Brown
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

6.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

7.  Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.

Authors:  D M Evans; P D Minor; G S Schild; J W Almond
Journal:  Nature       Date:  1983 Aug 4-10       Impact factor: 49.962

8.  Detection of Theiler's virus RNA in mouse central nervous system by in situ hybridization.

Authors:  W G Stroop; J R Baringer; M Brahic
Journal:  Lab Invest       Date:  1981-12       Impact factor: 5.662

9.  Rubredoxin from Desulfovibrio gigas. A molecular model of the oxidized form at 1.4 A resolution.

Authors:  M Frey; L Sieker; F Payan; R Haser; M Bruschi; G Pepe; J LeGall
Journal:  J Mol Biol       Date:  1987-10-05       Impact factor: 5.469

10.  The growth of four human and animal enteroviruses in the central nervous systems of mice.

Authors:  P Sethi; H L Lipton
Journal:  J Neuropathol Exp Neurol       Date:  1981-05       Impact factor: 3.685

View more
  11 in total

1.  Interaction of Theiler's virus with intermediate filaments of infected cells.

Authors:  P Nédellec; P Vicart; C Laurent-Winter; C Martinat; M C Prévost; M Brahic
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

2.  Mutation of predicted virion pit residues alters binding of Theiler's murine encephalomyelitis virus to BHK-21 cells.

Authors:  S Hertzler; M Luo; H L Lipton
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Intracerebral Inoculation of Mouse-Passaged Saffold Virus Type 3 Affects Cerebellar Development in Neonatal Mice.

Authors:  Osamu Kotani; Tadaki Suzuki; Masaru Yokoyama; Naoko Iwata-Yoshikawa; Noriko Nakajima; Hironori Sato; Hideki Hasegawa; Fumihiro Taguchi; Hiroyuki Shimizu; Noriyo Nagata
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

4.  Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B.

Authors:  I Tsunoda; Y Wada; J E Libbey; T S Cannon; F G Whitby; R S Fujinami
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Importance of amino acid 101 within capsid protein VP1 for modulation of Theiler's virus-induced disease.

Authors:  Y Wada; M L Pierce; R S Fujinami
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Genomic regions of neurovirulence and attenuation in Theiler murine encephalomyelitis virus.

Authors:  M A Calenoff; K S Faaberg; H L Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Genetic mapping of the ability of Theiler's virus to persist and demyelinate.

Authors:  A McAllister; F Tangy; C Aubert; M Brahic
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Predominant binding of Theiler's viruses to a 34-kilodalton receptor protein on susceptible cell lines.

Authors:  D R Kilpatrick; H L Lipton
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Alteration of amino acid 101 within capsid protein VP-1 changes the pathogenicity of Theiler's murine encephalomyelitis virus.

Authors:  A Zurbriggen; J M Hogle; R S Fujinami
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Replacement of loop II of VP1 of the DA strain with loop II of the GDVII strain of Theiler's murine encephalomyelitis virus alters neurovirulence, viral persistence, and demyelination.

Authors:  Y Wada; I J McCright; F G Whitby; I Tsunoda; R S Fujinami
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.